Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology

Partnership leverages Alloy’s high velocity antibody discovery offering to accelerate Normunity’s novel precision immuno-oncology pipeline

BOSTON--()--Alloy Therapeutics, a biotechnology ecosystem company, announced an antibody discovery collaboration spanning multiple precision immuno-oncology programs for Normunity, a biotech company that recently announced its $65 million Series A financing. The collaboration will support the advancement of Normunity’s immune normalizers, antibody therapies designed to target novel mechanisms that free the body’s normal immunity to fight cancer, which are conceived through a unique biotech-academic collaboration with a renowned immuno-oncology university research lab.

Alloy democratizes access to tools, technologies, and services that are foundational for discovering and developing therapeutic biologics and has partnered with more than 130 discovery teams across academia, biotech, and large biopharma organizations. Through its discovery services offering, Alloy conducts high-touch, bespoke therapeutic discovery campaigns against partners’ targets of interest.

“Our partnership reflects an exciting opportunity to pair Normunity’s insights in immune disruption and cancer disease biology with Alloy’s world-class antibody discovery expertise,” said Normunity Chief Scientific Officer William LaRochelle, PhD. “We value Alloy’s collaborative approach and look forward to working together to advance the best therapeutic antibodies to target mechanisms discovered through Normunity’s platforms.”

The collaboration between Alloy and Normunity is leveraging Alloy’s high velocity antibody discovery services offering, Daedamab, which takes a sequencing-first approach to antibody discovery that reduces discovery timelines without sacrificing quality. The Daedamab team is based in Alloy’s research facility in Athens, GA, and its workflow comprises the ATX-Gx™, Alloy’s proprietary mice platform for human therapeutic antibody discovery, in addition to robust B cell isolation, next generation sequencing, cloning-free expression and a high throughput screening process—all supported by a rich informatics engine.

“We are very excited to work with Normunity on its set of unique immuno-oncology targets using our high velocity NGS-based antibody discovery methods leveraging the ATX-Gx platform," said Richard Shimkets, PhD, SVP of Genetics and New Technologies at Alloy Therapeutics and CEO of the Daedamab site. “This relationship is emblematic of Alloy’s expertise in deploying the right technologies and processes to find our partners the best therapeutic antibodies against the novel targets they bring us.”

Normunity is advancing into the clinic with programs that target mechanisms that drive the exclusion of T cells into immune-sensitive tumors and aim to deliver an active and effective immune system into cold tumors.

About Daedamab

Alloy’s Daedamab discovery service offers a novel, fast, powerful sequence-first approach to finding and making the best antibodies. The team is based in Athens, GA and supports Alloy collaborators with complete antibody discovery services, antibody sequencing of customer-provided material, expression and testing of customer-provided antibody sequences, humanization, and optimization services.

About Alloy Therapeutics

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities, including antibodies, TCRs, genetic medicines, peptides, cell therapies, and drug delivery. Partners may access all current and future technologies for a flat annual fee through Alloy’s Innovation Subscriptions offering. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation.

Join the Alloy Therapeutics community by visiting alloytx.com, following Alloy on LinkedIn, scheduling a 15-minute introductory call with our team at alloytx.com/bd, or a 15-minute chat with Alloy’s Founder and CEO at alloytx.com/ceo.

About Normunity

Normunity, Inc., is a biotechnology company creating a new class of precision immuno-oncology medicines, called immune normalizers, that target novel mechanisms that free the body’s normal immunity against cancer. Based on an ongoing, interactive academic-biotech partnership with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is targeting newly-discovered mechanisms of immune disruption in cancer based on proprietary discovery platforms that elucidate the complex interactions between human cancer and the immune system. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. Normunity is located in Boston, Mass. and West Haven, Conn. For more information, please visit www.normunity.com.

Contacts

Erin Glabets
communications@alloytx.com

Contacts

Erin Glabets
communications@alloytx.com